Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Sepsis

Sponsor
Xijing Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05229328
Collaborator
(none)
300
1
13.2
22.8

Study Details

Study Description

Brief Summary

Sepsis is a clinical syndrome with high morbidity and high fatality rate in emergency department. Patients with acute liver or kidney injury are more likely to develop Multiple Organ Dysfunction Syndrome(MODS) secondary to the non-hepatic injury group, and the prognosis deteriorates significantly. At present, there is no unified diagnostic criteria for acute liver injury associated with sepsis, and the commonly used prognostic evaluation system is rarely included in liver injury indicators, which is not good for practicality.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Peripheral blood test

Detailed Description

The project intends to collect the peripheral blood of the normal population, 24 hours after the onset of sepsis and patients in the recovery period. We will separate and extract plasma, Peripheral Blood Mononuclear Cell(PBMC), and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis. And then, we will construct and verify the early warning and prognosis evaluation system.

On this basis, the researcher explore cellular and molecular mediated pathological mechanisms of sepsis, and then clarify the treatment target of sepsis.

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Study on the Establishment of a System for Early Warning and Prognostic Evaluation
Actual Study Start Date :
Oct 26, 2021
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Control group

Healthy volunteers

Diagnostic Test: Peripheral blood test
Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis

Patients within the acute phase of disease

Patients within 24 hours after onset

Diagnostic Test: Peripheral blood test
Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis

Recovery phase of disease

Inflammation was controlled, shock was corrected, and the patient remained fever free for 3 consecutive days.

Diagnostic Test: Peripheral blood test
Collect peripheral blood to separate and extract plasma, PBMC, and plasma exosomal miRNA, and sequence to find indicators related to disease deterioration and prognosis

Outcome Measures

Primary Outcome Measures

  1. Rate of Surviving or Died Participants with sepsis [Day 30]

    Prognosis

  2. Rate of Surviving or Died Participants with sepsis [Day 90]

    Prognosis

Secondary Outcome Measures

  1. Sepsis-associated liver injury [Day 0]

    Concentration of Alanine aminotransferase(ALT) >80 U/L or Glutamine oxaloacetic transaminase (GOT,AST) >80 U/L, Concentration of total bilirubin(TBIL)>2mg/dl(34μmol/l)

  2. Sepsis-associated kidney injury [Day 0]

    Concentration of Creatinine(Cr)>2 mg/dl or Urine output < 500ml/Day

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. The patient who voluntarily signs an informed consent form;

  2. Adult patients who meet the criteria for sepsis, who is registration to the hospital within 24 hours of onset;

  3. SEPSIS is defined as the sequential organ failure assessment (SOFA) score ≥ 2 within 24 hours after admission, accompanied by at least one site of infection;

  4. Patients with septic shock can be identified with a clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain mean arterial pressure(MAP) 65 mm Hg and having a serum lactate level >2 mmol/L (18 mg/dL) despite adequate volume resuscitation.

Exclusion Criteria:
  1. Age <18 years old or >90 years old;

  2. Patients with advanced tumors, Pregnancy or lactation;

  3. Patients who missed out during treatment and whose data are incomplete.

Contacts and Locations

Locations

Site City State Country Postal Code
1 The First Affillated Hospital,the Air Force Medical University Xi'an Shannxi China 710032

Sponsors and Collaborators

  • Xijing Hospital

Investigators

  • Study Chair: Yanyan Jia, The First Affillated Hospital,the Air Force Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Xijing Hospital
ClinicalTrials.gov Identifier:
NCT05229328
Other Study ID Numbers:
  • KY20212172
First Posted:
Feb 8, 2022
Last Update Posted:
Aug 18, 2022
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 18, 2022